[Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children]. / Khimiopreparaty v terapii grippa i drugikh respiratornykh virusnykh infektsii u detei.

Therapeutic efficacy of remantadine and arbidole was studied in the clinical and laboratory observation of pediatric in- and outpatients with grippe and mixed viral infections in various seasonal epidemic. In the trial of remantadine 742 school children and 60 children at the age of 3 to 6 years with type A, B or A + B grippe, grippe in association with other acute viral respiratory tract infections or acute viral respiratory tract infections of nongrippe etiology were observed. 402 and 400 of them were given remantadine and placebo respectively. The drug was used in a single dose of 1.5 mg/kg body weight 3 times a day for 3 days. In the trial of arbidole 158 children at the age of 1 to 14 years with type A grippe, grippe + acute viral respiratory tract infection and acute viral respiratory tract infection of nongrippe etiology were observed. The arbidole daily dose of 10 mg/kg body weight was given in 4 portions for 5 days. Both the drugs were shown to be therapeutically efficient in all the grippe types and acute viral respiratory tract infections. The highest efficacy was observed when the use of the drugs was started at the early stages. With the use of the drugs the periods of fever, other intoxication signs and virus isolation decreased. No adverse reactions were recorded. The drugs had no inhibitory effect on the cellular and humoral immunity and on production of antiviral antibodies. The dynamics of the indices of the cellular immunity and macrophages confirmed the arbidole immunostimulating action.

[The antiviral activity of deitiforin in experimental para-influenza infection]. / Protivovirusnaia aktivnost' deitiforina pri éksperimental'noi paragrippoznoi infektsii.

Deitiforin in HEp-2 cell culture was shown to inhibit replication of the reference PIV-3 strain when administered 1 hour before virus inoculation. The most marked effect of the drug was observed in the first 4 days of observation. In experimental newborn mice infected with parainfluenza virus 3 deitiforin protected the animals from developing the infection. In humans given deitiforin reaction to vaccination was found to develop 5-6 times more rarely than in the control group, PIV-3 could be isolated twice as rarely, and a diagnostically significant rise of specific antibody levels was observed less frequently.

[Interfering and interferonogenic activity of attenuated and original para-influenza viral strains]. / Interferiruiushchaia i interferonogennaia aktivnost' attenuirovannykh i iskhodnykh shtammov virusov paragrippa.

A higher interfering activity of attenuated (vaccine) strains of parainfluenza virus types 1, 2 and 3 which had undergone a long-term adaptation to cell cultures as compared to the original viruses was established. The interferon-inducing activity of vaccine parainfluenza virus types 2 and 3 was also higher than that of the original viruses. The high interfering and interferon-inducing activity of attenuated parainfluenza virus strains of type 2 and 3 correlated with reduced virulence of these variants for man. These tests may be used for the assessment of virulence of parainfluenza virus strains type 2 and 3 in the laboratory.

Reliability of the serological method of examination as a basis for diagnosis of associated respiratory virus infections.

The reliability of the results of serological examination in diagnostics of associated infections was studied on a model of artificially provoked vaccinal infections in humans and in laboratory animals. The effect of administered monopreparations on changes in the level of both homologous and heterologous antibodies was tested. The character of immunological changes following simultaneous administration of two or more respiratory viruses was analysed and the effect of these viruses in diseases of divers etiology was studied. According to the results of experiments on laboratory animals, repeated administration of any of the earlier used respiratory viruses stimulated the accumulation of only homologous antibodies while heterologous antibodies did not increase at all.

Reliability of the serological method of examination as a basis for diagnosis of associated respiratory virus infections.

The reliability of the results of serological examination in diagnostics of associated infections was studied on a model of artificially provoked vaccinal infections in humans and in laboratory animals. The effect of administered monopreparations on changes in the level of both homologous and heterologous antibodies was tested. The character of immunological changes following simultaneous administration of two or more respiratory viruses was analysed and the effect of these viruses in diseases of divers etiology was studied. According to the results of experiments on laboratory animals, repeated administration of any of the earlier used respiratory viruses stimulated the accumulation of only homologous antibodies while heterologous antibodies did not increase at all. The results revealed the possibility of simultaneous immunological reorganization of a child's organism in response to the influence of several different antigens from the group of respiratory viruses acting synchronously or in succession. Results of the analysis demonstrated the reliability of the employed serological methods of diagnosis of respiratory virus infections.